05 · FEMETRIC REFERENCE
Blood Work
A question-led guide to metabolic markers, the GH axis, CBC and CMP in peptide research contexts.No universal peptide panel
Testing depends on the compound, indication, health history, other medicines and the outcome being monitored. Femetric does not generate individualized laboratory orders.
Marker map
These groups describe where markers commonly appear in research or labeled monitoring. They are not a universal checklist.
| Marker area | Examples | Why it may appear | Common unit families |
|---|---|---|---|
| Metabolic | Glucose, HbA1c, fasting lipids | Glycemic and cardiometabolic outcomes | mg/dL, mmol/L, % |
| GH axis | IGF-1, sometimes GH | Downstream response or labeled safety monitoring | ng/mL, age-adjusted z-score |
| CBC | Hemoglobin, hematocrit, platelets, leukocytes | Blood-cell and safety context | g/dL, %, cells/uL |
| CMP | Creatinine, electrolytes, ALT, AST, bilirubin | Renal, hepatic and electrolyte context | mg/dL, mmol/L, U/L |
What makes a result interpretable
Record the research question, baseline timing, repeat timing, assay, units and source. Reference ranges vary. Fasting status, menstrual or reproductive context, hydration, recent illness and laboratory method can matter.
Where to continue
Use a compound page to identify the actual population and outcomes studied. For GH-axis context, see the Tesamorelin record. For metabolic outcomes, compare Tirzepatide and Retatrutide.
Primary and authoritative context
MedlinePlus, U.S. NLMMedical test encyclopediaU.S. FDATesamorelin prescribing informationNEXT RESEARCH ACTION